The information you are about to see is intended for US health care professionals
Please confirm you are a US health care professional
Carbonic anhydrase IX (CAIX):
Marking the future of ccRCC identification
This biomarker may offer a clearer path forward
Current diagnostic imaging cannot reliably characterize ccRCC.1 But what if there was a way to provide a clearer picture?
CAIX is a powerful, selective biomarker in RCC. CAIX is highly expressed in up to 95% of ccRCC tumors, with considerably lower expression in oncocytomas and chromophobe and papillary RCCs and no expression in normal renal tissue.2
CAIX-positive PET image adapted from data on file.3 Patient representative example, individual results may vary.
A BLA submission to the FDA is planned for an investigational 89Zr radiodiagnostic PET agent for the characterization of renal masses as ccRCC
Adding 89Zr to your license today may help shorten patients' time to an accurate ccRCC diagnosis
Ensuring your RAM license includes 89Zr will allow for timely access to this noninvasive diagnostic option, should it be approved.
An amendment to your facility's RAM license to include
89Zr licensing may take weeks to months.
Ensure your RAM license includes 89Zr
It’s time to see ccRCC clearly
GET MORE INFORMATIONBLA, biologics license application; ccRCC, clear cell renal cell carcinoma; FDA, Food and Drug Administration; PET, positron emission tomography; RCC, renal cell carcinoma.
References: 1. de Silva S, Lockhart KR, Aslan P, et al. Differentiation of renal masses with multi-parametric MRI: the de Silva St George classification scheme. BMC Urol. 2022;22(1):141. 2. Stillebroer AB, Mulders PFA, Boerman OC, Oyen WJG, Oosterwijk E. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol. 2010;58(1):75-83. 3. Data on file. Telix Pharmaceuticals, Ltd.